Fig 3.

OncoPrint of key pathways altered in the three groups of responders. The OncoPrint highlights the pattern of comutation of 20 genes stratified by response grade into excellent (Exc), intermediate (Int), or poor cohorts. The red arrow identifies the patient tumor treated with the MEK inhibitor for chronic myelomonocytic leukemia. Orange dots indicate complete response and still alive; yellow dots indicate complete response and dead or disease progression. Dark green indicates recurrent and/or activating missense mutation; a cutoff of six recurrences or more reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) in at least two tumor types was used to distinguish a recurrent mutation from a rare event. Light green indicates nonrecurrent missense variant of unknown significance; red indicates amplification; blue indicates deep deletion; black indicates truncating deletion; and orange indicates in-frame mutation.